Brazili - Kireno - ANVISA (Agência Nacional de Vigilância Sanitária)

laboratÓrios pfizer ltda - antibioticos antineoplasicos

Umoja wa Ulaya - Kireno - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - agentes antineoplásicos - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

Umoja wa Ulaya - Kireno - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Brazili - Kireno - ANVISA (Agência Nacional de Vigilância Sanitária)

accord farmacÊutica ltda - cloridrato de epirrubicina - antibioticos antineoplasicos

Umoja wa Ulaya - Kireno - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - carcinoma, células escamosas - agentes antineoplásicos - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Ureno - Kireno - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

hikma farmacêutica (portugal), s.a. - gemcitabina - concentrado para solução para perfusão - 38 mg/ml - gemcitabina, cloridrato 43.28 mg/ml - gemcitabine - n/a - duração do tratamento: longa duração

Ureno - Kireno - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

hikma farmacêutica (portugal), s.a. - oxaliplatina - concentrado para solução para perfusão - 5 mg/ml - oxaliplatina 5 mg/ml - oxaliplatin - genérico - duração do tratamento: longa duração

Ureno - Kireno - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

hikma farmacêutica (portugal), s.a. - cisplatina - concentrado para solução para perfusão - 1 mg/ml - cisplatina 1 mg/ml - cisplatin - genérico - duração do tratamento: longa duração

Ureno - Kireno - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

hikma farmacêutica (portugal), s.a. - cisplatina - concentrado para solução para perfusão - 1 mg/ml - cisplatina 1 mg/ml - cisplatin - genérico - duração do tratamento: longa duração

Ureno - Kireno - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

hikma farmacêutica (portugal), s.a. - gemcitabina - concentrado para solução para perfusão - 38 mg/ml - gemcitabina, cloridrato 43.28 mg/ml - gemcitabine - n/a - duração do tratamento: longa duração